Personalized medicine and therapeutic decision-making in oncology: a commentary on key environmental issues.
Freeman
Robert A
RA
Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas 78363, USA. freeman@pharmacy.tamhsc.edu
D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D018795:Device Approval; D004059:Diffusion of Innovation; D017277:Drug Approval; D033161:Government Regulation; D017048:Health Care Costs; D006291:Health Policy; D006301:Health Services Needs and Demand; D006801:Humans; D007349:Insurance, Health, Reimbursement; D008495:Medical Oncology / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods* / Q000639:trends; D057089:Pathology, Molecular / Q000191:economics / Q000331:legislation & jurisprudence / Q000639:trends; D018579:Patient Selection; D057285:Precision Medicine / Q000191:economics / Q000639:trends